Lacosamide NDC 50228-193

Product information

Brand name (proprietary)

Lacosamide

Generic name (nonproprietary)

lacosamide

Active ingredients

Lacosamide — 100 mg/1

Dosage form

Tablet, Film coated

Route

Oral

Labeler

ScieGen Pharmaceuticals Inc

Product type

Prescription drug

Marketing category

ANDA — Abbreviated New Drug Application (generic)Application ANDA 205237

Marketing start

Mar 18, 2022

Listing expires

Dec 31, 2026

DEA schedule

CV

Other FDA classes

Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)

Identifiers

Product ID 50228-193_56788345-3f8e-478c-b73d-216b4d711b57SPL ID 56788345-3f8e-478c-b73d-216b4d711b57SPL set ID f4ffa3ad-1278-4772-9ef8-ed6fdaa47605RxCUI 809987, 809992, 809996, 810000UNII 563KS2PQY5UPC 0350228195607, 0350228193603, 0350228194600, 0350228192606

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450228019310 followed by a unit qualifier and the quantity Copy

Package 50228-0193-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Other NDCs under ANDA 205237

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.